Poly Medicure Eyes H2 Rebound, FY27 Export Recovery & Product Expansion

• Poly Medicure expects 22-25% revenue growth in H2 and aims for 15-16% for FY26, despite previous export headwinds.
• Export markets are projected to recover in FY27, driven by European market recovery and a potential India-US trade deal.
• The company completed two acquisitions, expanding into trauma, ortho, and cardiology, with significant revenue contributions expected by FY27.
• Poly Medicure holds over ₹750 crore in cash for future acquisitions and plans to expand orthopaedics, cardiology, and oncology portfolios in CY26.
• While rupee weakness benefits exports, the domestic industry faces challenges from an inverted duty structure and lower GST on imported medical devices.

Why It Matters: Poly Medicure's strategy indicates future growth and market position.